Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in

  News Archive

Debiopharm and Solid Biosciences Announces Collaboration
Thursday, September 10, 2015
Debiopharm to start pre-clinical animal studies in Duchenne Muscular Dystrophy with Solid Biosciences.

Santhera Receives European Marketing Authorization for Raxone®
Thursday, September 10, 2015
First approved treatment for LHON and first approved treatment for a mitochondrial disease.

AstraZeneca, Univ. of Manchester Partner
Wednesday, September 09, 2015
AstraZeneca and The University of Manchester have announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients.

US FDA Grants Therapy Designation for Roche’s Investigational Medicine ACE910
Tuesday, September 08, 2015
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of haemophilia A.

Novartis Receives EU Approval for Farydak®
Tuesday, September 08, 2015
Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD.

New Strategy to Lower Blood Sugar May Help in Diabetes Treatment
Monday, September 07, 2015
Some treatments for type 2 diabetes make the body more sensitive to insulin, the hormone that lowers blood sugar. But new research at Washington University School of Medicine in St. Louis suggests a different strategy: slowing the production of glucose in the liver.

Dr John Hutchison Joins Autifony Therapeutics as Chief Medical Officer
Friday, September 04, 2015
Dr Hutchison brings a wealth of experience of clinical drug development in both big pharma and the biotech sector.

EU Approval For Tafinlar® and Mekinist®
Friday, September 04, 2015
Novartis have announced that the European Commission has approved the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Novartis, Amgen Partner
Friday, September 04, 2015
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule.

<< 7 8 9 10 11 12 13 >>
Showing Results 91 - 100 of 3902

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos